Where Global Innovation
and Capital Meet
Sectors Consumer University Energy Financial Healthcare Industrial IT Media Services Telecoms Transport The Art of CVC Startups

Page 434

UltraSense touches base with $20m series B

Touch-based user interface developer UltraSense secured the cash in a Robert Bosch-led round with contributions from Asahi Kasei and Sony.

Feb 19, 2020

Talent and capital keys to Silicon success

Intel Capital's Nick Washburn and Hyundai Cradle's John Suh on California's tech ecosystem

Feb 19, 2020

Skoda skips from Workday to Morgan Stanley

Workday Ventures has lost its vice-president of investments, Brittany Skoda, less than two years after she joined the corporate venturing unit from Goldman Sachs.

Feb 18, 2020

Carevive receives $15m in series C funding

Debiopharm Innovation Fund and Philips Health Technology Ventures both contributed to the latest round for the cancer care software producer.

Feb 18, 2020

Summit 2020 covers AI, dealflow and more

The Global Corporate Venturing and Innovation Summit 2020 in Monterey, California, brought together more than 800 corporate venturing leaders from corporations representing about $10 trillion in annual revenues.

Feb 18, 2020

Toast gets $400m meal

The Alphabet-backed restaurant management platform developer's series F round valued it at $4.9bn and it has now received more than $900m in funding altogether.

Feb 17, 2020

BlockFi locks in $30m

The crypto finance product developer has now raised more than $110m altogether, with CMT Digital returning for its series B round.

Feb 17, 2020

Datometry draws $17m in series B round

Dell Technologies Capital reinvested as part of a series B round for the virtualisation platform developer having backed its series A in 2017.

Feb 17, 2020

Corporate venturing deal net: 10-14 February 2020

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds

Feb 14, 2020

Revolution hits public markets in $238m IPO

The precision cancer therapy developer, which counts Sanofi as a significant shareholder, floated at the top of an upsized range and saw its price continue to rise post-IPO.

Feb 14, 2020

© 2024 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here